Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: *in vivo* and clinical studies

Zhengang Sun1*, Zizhuo Zhao2*, Gaopeng Li2,3*, Shengl Li4, Zhiyong Huang3, Lu Ye5, Huifang Liang3, Junyuan Qu6, Xi Ai3, Wanguang Zhang3, and Xiaoping Chen3

1Department of Hepatobiliary Surgery, Jingzhou Central Hospital, JingZhou, Hubei Province; 2Department of Ultrasound, the second affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong Province; 3Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province; 4Department of General Surgery, the second affiliated hospital, Shanxi Medical University, Taiyuan, Shanxi Province; 5Infection Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province; 6Department of Galactophore Surgery, Shanxi Tumour Hospital, Taiyuan, Shanxi Province, China

*These authors contributed equally to this work and should be considered co-first authors.

**ABSTRACT**

Aims and background. A former study evaluated the roles of four multidrug resistance-related proteins, namely multidrug resistance protein 1 (MDR1), breast cancer resistance protein (BCRP), multidrug resistance-related protein (MRP1), and lung resistance-related protein (LRP), in the MDR mechanism of the multidrug resistant hepatoma HepG2/ADM cell line and proposed that up-regulated MDR1 and BCRP are responsible for the MDR of hepatocellular carcinoma. This work aims to confirm that assumption *in vivo* and in clinical specimens.

Methods. First, the chemotherapeutic resistance of subcutaneous HepG2/ADM tumor and hepatocellular carcinoma samples post-transarterial chemoembolization (TACE) was determined by MTT, contrary to subcutaneous HepG2 tumor and hepatocellular carcinoma samples without TACE, respectively. Then, the mRNA and protein differential expression of the four genes between the MDR tissues and drug-sensitive tissues were quantitatively investigated by real-time RT-PCR and enhanced chemiluminescence western blot analysis, respectively.

Results. 1) mRNA expression of BCRP and MDR1 was respectively amplified 38.3 and 20.1 fold in tumors of HepG2/ADM mice compared to those of HepG2 mice, whereas they were respectively augmented for 14.6 and 9.3 times in TACE samples, contrary to the tumor tissues without TACE. 2) The protein presence of MDR1 and BCRP in MDR tumors was also significantly higher than those in the control group *in vivo* and in clinical specimens. 3) The mRNA expressions of MDR1 and BCRP were correlated with their protein levels.

Conclusions. The study showed that MDR1 and BCRP may be the most important factors for drug resistance in hepatocellular carcinoma. Moreover, the positive correlation between their mRNA and protein expression indicates the easy prediction of HCC MDR and possible inhibitive target of drug resistance at multi-levels. Free full text available at www.tumorionline.it

**Key words:** athymic mice, hepatocellular carcinoma, multi-drug resistance protein, multi-drug resistance.